Introduction {#Sec1}
============

Colorectal cancer (CRC) remains one of the most common cancers worldwide, and accounts for 12% of all cancer-related deaths in Europe.^[@CR1]^ The epidermal growth factor receptor (EGFR) has become an important therapeutic target in CRC,^[@CR2]^ but \~40% of patients with metastatic colorectal cancer (mCRC) have tumours with mutations in *KRAS* and are not expected to respond to treatment with the anti-EGFR monoclonal antibodies cetuximab and panitumumab.^[@CR3],[@CR4]^ Several studies have shown that an extended analysis of *RAS* mutations (including *KRAS* exons 2, 3, and 4 and *NRAS* exons 2, 3, and 4) may optimise the identification of patients most likely to benefit from anti-EGFR therapy,^[@CR5]--[@CR9]^ and clinical practice guidelines in the US and Europe include the indication for expanded *RAS* testing before the use of anti-EGFR agents.^[@CR10]--[@CR12]^

Typically, the evaluation of *RAS* mutation status requires the acquisition of tumour tissue, subsequent processing to formalin-fixed, paraffin-embedded (FFPE) specimens and molecular testing with various techniques. As an alternative, the analysis of circulating tumour DNA (ctDNA) can provide a rapid genotype result with a streamlined clinical workflow and minimal disturbance to the patient. The recent approval of the OncoBEAM RAS CRC liquid biopsy assay by the European Commission as an in vitro diagnostic tool allows a practical and sensible approach for determination of *RAS* mutations in ctDNA.^[@CR13]^

In this study, which included 10 hospital centres across Spain certified to run OncoBEAM RAS in routine practice, we evaluated the concordance between *RAS* status determined by OncoBEAM in plasma and the reference test performed on tissue at each centre from a large cohort of mCRC patients. We also examined the characteristics of discordant cases and the mutant allele fraction (MAF) in *RAS* mutated patients.

Patients and methods {#Sec2}
====================

Study design and patients {#Sec3}
-------------------------

This was a multicenter, prospective, real-world study performed in 10 Spanish centres from November 2015 to October 2016. The study was approved by the Institutional Review Board at each hospital and was conducted in accordance with the principles of the Declaration of Helsinki. Prior to participation, all patients signed the inform consent form. Newly-diagnosed mCRC patients or presenting with recurrent disease after resection and/or chemotherapy were eligible. Patients having surgery with total disease removal or that received the last cycle of chemotherapy \<6 months prior to blood draw were excluded.

Procedures {#Sec4}
----------

Plasma was obtained from 10 ml of blood collected in Streck cell-free DNA BCT® or EDTA tubes before any therapeutic intervention. All patients had FFPE tissue (either primary tumour or metastasis) available for mutation analysis. OncoBEAM™ RAS CRC assay, which detects 34 mutations in *KRAS/NRAS* codons 12, 13, 59, 61, 117, and 146, was used to analyse *RAS* mutations and determine MAF in plasma. The mutation profile in tissue samples was determined by standard-of-care (SoC) procedures validated by each hospital (Supplementary Table [S1](#MOESM1){ref-type="media"}). Tissue *RAS* testing by BEAMing (1% mutant allele cut-off) was centrally performed by the Service Laboratory of Sysmex Inostics. The commercially available mutation testing service using the RAS OncoBEAM panel (33 single mutations, covering the same base exchanges like the IVD kit product OncoBEAM™ RAS CRC assay) was used in the laboratory of Sysmex Inostics GmbH, Hamburg (Germany) on FFPE samples from every patient case where the SoC *RAS* result was discordant with the plasma *RAS* result. The same tissue block was used for the central re-analysis by BEAMing.

Statistical analysis {#Sec5}
--------------------

Categorical variables were summarised in numbers and percentages, continuous variables were presented as medians, minima and maxima. Concordance between plasma and tissue RAS testing was determined using a Kappa statistic (kappa) with 95% confidence interval (CI). Positive percent agreement (PPA), negative percent agreement (NPA) and overall percent agreement (OPA) were also calculated. For MAF levels correlations with clinical variables, we performed non-parametric statistics (Mann--Whitney *U* test for dichotomous and Kruskal--Wallis test for polychotomous variables). All statistical tests were considered significant when *P* \< 0.05. Statistical analyses were performed using the SAS version 9.4 statistical software.

Results {#Sec6}
=======

Patient characteristics and RAS mutation status analysis from plasma and tissue {#Sec7}
-------------------------------------------------------------------------------

A total of 239 mCRC patients were initially included, 3 of which were excluded because total disease removal during primary surgery. The remaining 236 participants, 144 men and 92 women, comprised the study population (see their baseline characteristics in Table [1](#Tab1){ref-type="table"}). The majority of patients (95.4%) had colorectal adenocarcinoma with distant metastases at diagnosis (85.1%), 50.4% underwent surgery to remove the primary tumour or some portion of metastasis (16.9%) before blood sample collection. The most frequent site of metastasis was the liver (71.2%) followed by the lung (29.3%).Table 1Summary of patient/tumour characteristics and mutational analysisNumberPercentageAge in years Median (range)65 (33--89)---Gender Male14461% Female9239%Time since diagnosis (days) Median (range)44 (0--3971)---Primary site Right7130.1% Left16268.6% Not available31.3%Histological type Adenocarcinoma22595.3% Other114.7%Number metastatic sites at ctDNA collection 114561.4% 27431.4% 3+177.2%Metastatic site Liver (only in liver)168 (90)71.2% (38.1%) Lung (only in lung)69 (16)29.3% (6.8%) Peritoneal (only peritoneal)63 (25)26.7% (10.6%) Other (only other)46 (14)19.5% (5.9%)Tumour sample for *RAS* testing Primary20487.2% Metastasis3012.8%Plasma BEAMing result Mutated12151.3% WT11548.7%Tissue SOC result Mutated13155.5% WT10544.5%Tissue SOC + Tissue BEAMing result Mutated12854.2% WT10845.8%MAF (plasma) Median (range)2.9 (0--68)---*MAF* Mutated allele fraction, *SOC* standard of care, *WT* wild-type

*RAS* mutation status was evaluable in both plasma and tissue of all 236 patients. Overall, *RAS* mutations were detected in 55.5% of tumour-tissue samples and in 51.3% of plasma samples (Table [1](#Tab1){ref-type="table"}). The OPA of *RAS* results between ctDNA and SoC for tissue analysis was 89% (210/236 patients), with a kappa index of 0.770 (95% CI: 0.689--0.852) (Fig. [1a](#Fig1){ref-type="fig"}). To clarify the 26 discrepant *RAS* status results, all FFPE samples except one (not available) were centrally re-analysed by BEAMing technology (Table [2](#Tab2){ref-type="table"}). Of the 18 plasma WT/*RAS*+ cases, five were finally concordant (Plasma WT/Tissue SoC Mutated/Tissue BEAMing WT); of the 8 plasma *RAS*+/tissue WT cases, two were concordant (Plasma BEAMing Mutated/Tissue SoC WT/Tissue BEAMing Mutated). This final analysis resulted in a total 217 concordant patients from the 236, representing a 92% overall concordance (*κ*: 0.853, 95% CI: 0.786--0.920) (Fig. [1b](#Fig1){ref-type="fig"}).Fig. 1Concordance between plasma and tissue results obtained by SOC (**a**) or SOC + BEAMing (**b**). SOC standard of careTable 2Descriptive summary of discordant plasma-tissue cases (*n* = 26)Case IDSurgery of primary tumour?Surgery of metastases?Date of tissue biopsyDate of blood collectionPlasma BEAMing resultTissue SOC result (method)Tissue BEAMing resultSite of metastasesMetastasis excised by surgeryType of sample14383YesYes01/09/201528/01/2016WTMutated (Pyroseq)WTLungLungMetastasis14657YesNo25/11/201303/03/2016WTMutated (Pyroseq)WTPeritoneal, otherPrimary tumour14301YesNo27/11/201330/03/2016WTMutated (Therascreen)WTLungPrimary tumour14347NoNo19/04/201606/05/2016WTMutated (Pyroseq)WTPeritoneal, otherPrimary tumour14402NoNo03/06/201630/06/2016WTMutated (Pyroseq)WTLiverPrimary tumour14333NoNo28/10/201514/04/2016KRAS12 0.262WT (Pyroseq)KRAS12 4.104%PeritonealPrimary tumour14312NoNo05/05/201601/06/2016KRAS13 11.4WT CLART− CMA Kit+ (Pyroseq)KRAS13 16.796%Liver, lungPrimary tumour14365YesYes03/05/201201/12/2015WTMutated (Pyroseq)KRAS12 37.709%LungLungPrimary tumour14486YesYes15/12/201503/12/2015WTMutated (Pyroseq)KRAS13 6.193%RetroperitonealLungMetastasis14493YesYes05/02/201605/02/2016WTMutated (Pyroseq)KRAS 13 26.058%LiverLiverMetastasis14527YesNo27/03/201603/03/2016WTMutated (Pyrosequ)KRAS12 8.469%Peritoneal, rectumPrimary tumour14477NoNo01/08/201601/09/2016WTMutated (Therascreen)KRAS13 5.586%LiverPrimary tumour14335YesNo19/11/200914/04/2016WTMutated (Pyroseq)KRAS146 28.706%Lung, peritonealPrimary tumour14327YesNo05/09/201306/06/2016WTMutated (Pyroseq)Not availableLungPrimary tumour14329YesYes01/04/201606/06/2016WTMutated (Pyroseq)KRAS13 43.203%LungLungMetastasis14385YesNo04/04/201411/07/2016WTMutated (Pyroseq)KRAS12 30.146%PeritonealPrimary tumour14651YesNo18/08/201627/09/2016WTMutated (Pyroseq)KRAS12 8.96%LungPrimary tumour14410YesYes10/05/201622/06/2016WTMutated (Therascreen)KRAS12 35.181%Liver, suprarrenal, rectalLiverPrimary tumour14569YesNo11/11/201316/09/2016WTMutated (Idylla)KRAS12 4.267%LungPrimary tumour14669NoNo29/09/201614/10/2016WTMutated (Cobas)KRAS13 1.300%LiverPrimary tumour14387NoNo28/06/201605/09/2016KRAS12 0.021WT (Pyroseq)WTBonePrimary tumour14545YesYes18/09/201511/07/2016NRAS13 0.349WT (Pyroseq)WTLiver, lung, lymph nodesLiverPrimary tumour14355YesNo14/10/201529/02/2016KRAS12 0.128WT (Therascreen)WTLiverPrimary tumour14717NoNo07/11/201608/01/2016KRAS13 0.047WT (Therascreen)WTLiver, lungPrimary tumour14391YesNo10/12/201507/03/2016KRAS13 5.32WT (Pyroseq)WTLiverPrimary tumour14646YesYes30/03/201615/04/2016KRAS12 0.038WT (Therascreen + Pyroseq)WTOvaricOtherPrimary tumourThe seven first cases were finally concordant according to plasma-tissue BEAMing paired results*MAF* mutated allele fraction, *Pyroseq* pyrosequencing, *SOC* standard of care, *WT* wild-type

Discordant samples description and factors affecting concordance {#Sec8}
----------------------------------------------------------------

Among the samples with discordant *RAS* status between ctDNA and tissue BEAMing (*n* = 19), we observed that 5 of 13 Plasma WT/*RAS*+ Tissue cases involved patients that had exclusively lung metastases (Table [2](#Tab2){ref-type="table"}). Among the group with *RAS*+ Plasma/Tissue WT discordance, the sites of metastases in these 6 patients were widely distributed, including locations such as ovary and bone.

Table [3](#Tab3){ref-type="table"} shows concordant/discordant paired samples according to different clinical and pathological factors. Concordance was lower (87.4% vs 95.7%; *P* = 0.033) in cases where primary tumour surgery was initially performed. Those with metastatic disease at diagnosis had a higher agreement than patients without metastasis (94.5% vs 78.1%; *P* = 0.006). A higher concordance of plasma and tissue *RAS* results was observed in patients having liver metastases (94.5--94.8%) versus those not having liver metastases (83.8%; *P* *=* 0.040), whereas the lowest concordance rate was associated with the presence of lung metastases only (68.8%).Table 3Plasma BEAMing vs tissue SOC + BEAMing concordance according to clinical and pathological variablesVariableConcordance (%)*P*-valuePlasma MAF\
Median (range)*P* valueAge (years)  ≤6587.60.8243.3 (0--68)0.459  \>65882.7 (0--51.8)Primary tumour resection  No95.7**0.033**6.9 (0--68)**0.049**  Yes87.41.8 (0--26.8)Metastasis resection  No93.4**0.007**3.9 (0--68)0.169  Yes79.11.3 (0--24.6)Histological type  Adenocarcinoma920.2363.5 (0--68)0.080  Other81.80.2 (0--15.1)Metastases at diagnosis  No78.1**0.006**3.9 (0.2--24.7)0.319  Yes94.52.6 (0--68)Primary tumour location  Left96.20.4833.9 (0--51.8)0.351  Right89.92.8 (0--68)  Not available10011.7 (11.4--12)Number of metastases  1911.0002 (0--68)0.074  291.93.9 (0--35.7)  \>294.113 (0.3--51.8)Metastatic site  Only liver metastasis94.5**0.040**2.7 (0--68)0.052  Liver and other sites94.86.7 (0--51.8)  Without liver metastasis83.81.1 (0--26.8)Metastatic site  Only lung metastasis68.8**0.012**0.7 (0.1--24.7)0.092  Lung and other sites92.510 (0--51.8)  Without lung metastasis93.42.4 (0--68)Metastatic site  Only peritoneal metastasis95.80.7381.3 (0.1--26.8)0.835  Peritoneal and other sites89.71.8 (0--51.8)  Without peritoneal metastasis91.33.6 (0--68)Source of tissue sample  Metastasis900.7281.2 (0.1--51.8)0.559  Primary tumour91.73.5 (0--68)*MAF* mutated allele fraction, *SOC* standard of careBold values to remark a statistically significant difference

MAF analysis in mutated plasma samples {#Sec9}
--------------------------------------

For the 121 patients with detectable plasma *RAS* mutations, the median MAF \[range\] was 2.9% \[0--68\]. No differences in mutational load were observed in relation to age, tumour histology, metastasis at diagnosis, or primary site of disease (Table [3](#Tab3){ref-type="table"}). The median MAF in ctDNA according to the number of metastatic sites was 2% \[0--68\] in those with one metastatic site, 3.9% \[0--35.7\] in those with two metastatic sites, and 13% \[0.3--51.8\] in those with three or more (*P* *=* 0.074). The median MAF for those with at least one liver metastasis was 6.7% \[0--51.8\], whereas the patients with metastases only in the lung showed a median of 0.7% \[0.1--24.7\].

Discussion {#Sec10}
==========

A timely assessment of the current *RAS* mutation profile of mCRC patients provides the opportunity to deliver the most optimal therapy regimen matched to tumour molecular status.^[@CR14]^ With a liquid biopsy we can determine the presence of circulating tumour cells (CTCs), cancer‐derived exosomes, and ctDNA. Despite the technological advances in identifying and characterising CTCs, there are still significant biological challenges that limit their clinical application.^[@CR15]^ As ctDNA is released from primary tumours, CTCs, micrometastasis or overt metastases, this might better reflect the molecular changes that occur during disease progression.^[@CR16]^ Mutations in ctDNA may be detected in blood using several techniques, such as digital PCR (dPCR) assays such as droplet-digital PCR (ddPCR) and BEAMing, or next-generation sequencing (NGS). dPCR platforms offer easy workflow and better allele-specific sensitivity and reproducibility than standard quantitative PCR, but are limited in its multiplexing capability.^[@CR17]^ When multiple targets have to be analysed, NGS technology reduces the cost of screening compared to analysis with a lower throughput technology.^[@CR18]^ The principles and different characteristics of these techniques have been reviewed elsewhere.^[@CR13],[@CR19]^

To the best of our knowledge, this is the first prospective real-world study in which a *RAS* mutational analysis was compared between plasma OncoBEAM RAS CRC assay and tissue-based techniques in a network of hospital laboratories certified to perform OncoBEAM testing in routine clinical practice. Overall, a high concordance rate of *RAS* status was observed between plasma and tissue analysis performed by SoC procedures (89%). This rate was even better when certain tissue specimens which were seemingly mischaracterised by the local SoC technique were re-evaluated with BEAMing (92%). These results support the use of plasma testing with the OncoBEAM platform as a valuable alternative to tissue SoC to identify patients eligible for anti-EGFR therapy in routine clinical practice. Moreover, concordance rates are comparable to those obtained in previous retrospective and prospective studies,^[@CR20]--[@CR22]^ which corroborate the consistency of the technique among different mCRC patient populations. In fact, the frequency of *RAS* mutations in patients evaluated in this study was in agreement with the results of other groups performing expanded *RAS* analysis (plasma 51.3%; tissue 55.5%).^[@CR21]--[@CR23]^

Some reports have demonstrated that testing of DNA from a single colorectal tumour tissue block will wrongly assign *KRAS* wild-type status in 8--11.6% of patients.^[@CR24],[@CR25]^ Thus, the sole reliance on *RAS* mutation results obtained from a primary tumour sample might misinform effective treatment of residual systemic disease, imposing significant costs both clinically and financially. This sampling bias could largely be avoided by determining the *RAS* mutational status on multiple tumour blocks, but this is neither practical nor feasible. Studies evaluating inter-tumour heterogeneity between primary tumours and metastases have also revealed mutational discordance in a significant proportion of cases^[@CR26]--[@CR28]^ with high levels of inter-tumour heterogeneity observed between primary tumour and matched lung metastases (32.4%).^[@CR27]^ Thus, mCRC patients eligible for surgical resection can have primary tumours with a *RAS* mutation and metastases without *RAS* mutations, and vice-versa. Though there is no definitive guideline for determining which sample should be tested for *RAS* mutations, it is often the case in metastatic disease that the primary site is surgically resected while distant metastases are treated with systemic therapy.

Previous studies have shown that BEAMing is an accurate technique for the mutational analysis of archival FFPE tumour tissue.^[@CR6],[@CR8],[@CR29]^ In the present study, we found seven cases in which BEAMing identified the same *RAS* mutation in tissue that was identified in plasma, contrary to the original SoC result. Differences in tissue *RAS* mutation detection capabilities ranging between 3 and 20% among diverse routine methodologies have been reported,^[@CR30]--[@CR32]^ possibly associated with different sensitivity thresholds.^[@CR20]^ Accordingly, the agreement between plasma and tissue *RAS* testing results will likely improve when both the methods of plasma and FFPE preparation are standardised, underlying the importance of selecting a reliable laboratory for routine testing.^[@CR33]^ In our population, 13 patients had mutations in tissue that could not be detected in plasma, which may be attributed to tumour heterogeneity, low ctDNA shedding or low tumour burden. In fact, five of these discordant cases had archival primary tumour mutated and excised, maybe their metastases were WT or low-shedding lesions. Other authors found similar results in patients with *RAS* mutant on tissue and WT on liquid biopsy that had recurrence of the disease after surgical resection of the primary and a lower tumour burden, with metastatic lesions often localised in the lung and lymph nodes.^[@CR34]^ This finding is consistent with the significantly lower MAF found in our cohort of patients subjected to primary tumour resection. In line with this, our results also showed that the degree of *RAS* mutational concordance varied according to the metastatic site, with more discrepancies in patients with lung only metastases and a higher agreement in liver metastases; similarly, Thierry et al found higher specificity of plasma mutation analysis in patients with at least one liver metastasis,^[@CR35]^ whereas Kim et al.,^[@CR27]^ reported higher discordance rates when compared paired primary tumour and lung samples, so it is possible that lung metastases more frequently have a different *RAS* status than other metastatic sites. Another explanation may be that tumour budding in the metastatic lesions triggers different levels of ctDNA release. Metastatic deposits in the liver are likely highly vascularised as compared to the lungs, and this may contribute to greater levels of ctDNA released in the bloodstream.

Here, the median MAF obtained by plasma BEAMing was 2.9%, higher than in Vidal et al. (1.84%)^[@CR22]^ but lower than Schmiegel et al. (6.82%).^[@CR21]^ In the first study, 8 of the 59 *RAS*+ patients had received previous treatment with chemotherapy ± anti-VEGF within a month prior ctDNA blood extraction and showed significantly lower *RAS* plasma MAF as compared to treatment-naive patients, whereas our population had at least 6 treatment-free months before plasma collection. It has been reported that changes in ctDNA may occur during the course of the chemotherapy, with significant reductions in ctDNA levels observed even after the first cycle.^[@CR29]^ Thus, mutational load in patients exposed to therapy may decrease in parallel to radiological response.^[@CR36],[@CR37]^ Indeed, Schmiegel et al.^[@CR21]^ included a cohort of stage IV newly diagnosed patients with intact primary CRC whose MAF was 6.5-fold higher (9.63%) compared with those patients who presented with recurrent disease after removal of their primary tumours (1.49%). These findings highlight the significance of determining and monitoring the MAF of *RAS*+ mCRC patients throughout the course of the disease management and the impact of any surgical procedure and/or systemic treatment on it. Moreover, based on our results, the rate of release of tumour DNA into circulation may serve as an important clinical observation to consider, as highly vascularised metastatic sites (i.e. liver) and an elevated number of metastases were associated with higher MAF values.

In conclusion, ctDNA analysis by OncoBEAM RAS CRC assay is comparable to SoC tissue testing techniques. It represents a minimally invasive method easily implemented in routine clinical practice to rapidly determine mCRC patient eligibility for anti-EGFR therapy. This technique likely avoids the potential pitfalls of selecting a targeted therapy strategy based on the molecular profile of a single lesion. A unique feature of ctDNA genotyping is its ability to evaluate the extent of an individual patient's tumour burden, eliminating sampling issues related to tissue molecular heterogeneity and the development of mutations during the metastatic process.
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